Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...

Interdisciplinary Genitourinary Cancer Forum featured a metastatic urothelial carcinoma session and a presentation by Dr.

(UroToday.com)The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr. David ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...

Interdisciplinary Genitourinary Cancer Forum featured a metastatic castration resistant prostate cancer (mCRCP) session and a ...